Quince Therapeutics (QNCX) Price & Analysis

Compare

898 Followers

QNCX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.69 - $2.45

Previous CloseN/A

Volume30.57K

Average Volume (3M)164.56K

Market Cap

$86.48M

Enterprise Value$59.81M

Total Cash (Recent Filing)$34.71M

Total Debt (Recent Filing)$17.38M

Price to Earnings (P/E)―

Beta-0.20

Next Earnings

Nov 13, 2025

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding53,713,800

10 Day Avg. Volume243,793

30 Day Avg. Volume164,560

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.69

Enterprise Value/Revenue356.03

Enterprise Value/Gross Profit-866.84

Enterprise Value/Ebitda-1.21

Forecast

1Y Price Target

$8.67

Price Target Upside438.51% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Patient BenefitThe AIDE technology used by Quince allows for a simple and safe point-of-care treatment, which is beneficial for patients avoiding daily steroid side effects.

Study EnrollmentThe ongoing P3 study of eDSP in ataxia-telangiectasia has exceeded 75% enrollment, indicating strong progress.

Technology AdvantageThe company's AIDE technology allows for the effective delivery of dexamethasone with fewer safety concerns compared to traditional methods.

Bears Say

Enrollment ChallengesEnrollment in the P3 NEAT study is slower than expected, which has led management to consider concluding enrollment early.

Financial PerformanceQuince reported 4Q24 and 2024 results with a net loss of ($12.5M) and ($56.8M), respectively, which included $25.4M in non-cash items.

Past Study OutcomesThere is a history of a prior P3 study missing its primary endpoint, though a subgroup of kids aged 6-9 reached statistical significance.

Quince Therapeutics News

Quince Therapeutics Amends Credit Facility Agreement

Quince Therapeutics ( ($QNCX) ) has provided an update. On September 25, 2025, Quince Therapeutics amended its unsecured...

3d ago

QNCX

Quince Therapeutics price target lowered to $8 from $9 at Citizens JMP

Citizens JMP lowered the firm’s price target on Quince Therapeutics (QNCX) to $8 from $9 and keeps an...

2M ago

QNCX

Quince Therapeutics Reports Q2 2025 Financial Results

Quince Therapeutics ( ($QNCX) ) has released its Q2 earnings. Here is a breakdown of the information Quince...

2M ago

QNCX

Quince Therapeutics reports Q2 EPS (34c), consensus (23c)

Reported cash, cash equivalents, and short-term investments of $34.7 million for the second quarter ended June 30, 2025....

2M ago

QNCX

QNCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Quince Therapeutics (QNCX) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street analysts...

2M ago

QNCX

Quince Therapeutics initiated with an Outperform at Citizens JMP

Citizens JMP initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $9 price target The firm...

2M ago

QNCX

Quince Therapeutics files to sell 6.67M shares of common stock for holders

17:08 EDT Quince Therapeutics (QNCX) files to sell 6.67M shares of common stock for holders Published first on...

2M ago

QNCX

Quince Therapeutics Completes Enrollment for Phase 3 Trial

Quince Therapeutics ( ($QNCX) ) has provided an update. On July 16, 2025, Quince Therapeutics announced the completion...

3M ago

QNCX

Quince Therapeutics completes enrollment in NEAT clinical trial

Quince Therapeutics (QNCX) announced that the company has completed enrollment in its pivotal Phase 3 NEAT clinical trial...

3M ago

QNCX

Quince Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $8 price...

3M ago

QNCX

Quince Therapeutics Raises $11.5M in Private Placement

Quince Therapeutics ( ($QNCX) ) has shared an announcement. On June 12, 2025, Quince Therapeutics, Inc. entered into...

4M ago

QNCX

Quince Therapeutics prices up to $22M placement of securities

Quince Therapeutics (QNCX) “announced that it has entered into a securities purchase agreement with certain institutional and accredited...

4M ago

QNCX

Quince Therapeutics Approves Key Proposals at Annual Meeting

The latest update is out from Quince Therapeutics ( ($QNCX) ). On June 4, 2025, Quince Therapeutics, Inc....

4M ago

QNCX

Quince Therapeutics tops 75% enrollment in pivotal Phase 3 NEAT clinical trial

Quince Therapeutics (QNCX) “announced that its pivotal Phase 3 NEAT clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia...

4M ago

QNCX

QNCX FAQ

What was Quince Therapeutics’s price range in the past 12 months?

Quince Therapeutics lowest stock price was $0.69 and its highest was $2.45 in the past 12 months.

What is Quince Therapeutics’s market cap?

Quince Therapeutics’s market cap is $86.48M.

When is Quince Therapeutics’s upcoming earnings report date?

Quince Therapeutics’s upcoming earnings report date is Nov 13, 2025 which is in 45 days.

How were Quince Therapeutics’s earnings last quarter?

Quince Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.252 by -$0.088.

Is Quince Therapeutics overvalued?

According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quince Therapeutics pay dividends?

Quince Therapeutics does not currently pay dividends.

What is Quince Therapeutics’s EPS estimate?

Quince Therapeutics’s EPS estimate is -0.22.

How many shares outstanding does Quince Therapeutics have?

Quince Therapeutics has 53,713,800 shares outstanding.

What happened to Quince Therapeutics’s price movement after its last earnings report?

Quince Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.252. Following the earnings report the stock price went up 14.375%.

Which hedge fund is a major shareholder of Quince Therapeutics?

Currently, no hedge funds are holding shares in QNCX

Quince Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-167.04%

Trailing 12-Months

Asset Growth

-13.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Quince Therapeutics

Quince Therapeutics (QNCX) is a biopharmaceutical company focused on developing innovative treatments for patients suffering from chronic and debilitating diseases. Operating within the healthcare and biotechnology sectors, Quince Therapeutics leverages advanced scientific research and cutting-edge technology to design and develop therapeutic solutions aimed at addressing unmet medical needs. The company's core products include a pipeline of drug candidates that target specific molecular pathways implicated in various diseases.

Quince Therapeutics (QNCX) Earnings & Revenues

Historic Earnings Reports

QNCX Stock 12 Month Forecast

Average Price Target

$8.67

▲(438.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,2.246153846153846,2.8923076923076927,3.5384615384615388,4.184615384615385,4.830769230769231,5.476923076923077,6.123076923076923,6.76923076923077,7.415384615384616,8.061538461538461,8.707692307692309,9.353846153846154,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,2.143846153846154,2.687692307692308,3.2315384615384617,3.7753846153846156,4.319230769230769,4.863076923076923,5.406923076923077,5.950769230769231,6.4946153846153845,7.038461538461538,7.582307692307692,8.126153846153846,{"y":8.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,2.0923076923076924,2.5846153846153848,3.076923076923077,3.5692307692307694,4.061538461538461,4.553846153846154,5.046153846153846,5.538461538461538,6.030769230769231,6.523076923076923,7.015384615384615,7.507692307692308,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.88,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >